Results of the TRIGGER-PCI trial reported at TCT 2011

November 09, 2011

SAN FRANCISCO, CA - NOVEMBER 9, 2011 - A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was ended early due to relatively few occurrences of cardiac death or myocardial infarction - the primary endpoint - at six month follow up.

Results of the TRIGGER-PCI (Testing platelet Reactivity In patients underGoing elective stent placement on clopidogrel to Guide alternative thErapy with pRasugrel) trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

The risk of ischemic events after percutaneous coronary intervention (PCI) is elevated in patients with high on-clopidogrel platelet reactivity (HCPR). Novel P2Y12-receptor antagonists, such as prasugrel, are more potent than clopidogrel and may, thus, improve outcome with respect to ischemic events, but may also increase bleeding risk.

The trial was a multi-center, double-blind, randomized controlled trial. Platelet reactivity was assessed two to seven hours after the first maintenance dose of clopidogrel 75 mg on the day after PCI following loading with clopidogrel 600 mg and randomized to either prasugrel or clopidogrel. TRIGGER-PCI aimed to randomize 2,150 patients to have a 93% power for detecting a 50% relative risk reduction on prasugrel in the primary study endpoint (cardiovascular death or myocardial infarction within six months).

The study was terminated prematurely for futility at March 18, 2011 at which 236 patients completed the six-month follow up. Only one clinical endpoint, a peri-procedural myocardial infarction, was observed.

"High on-clopidogrel platelet reactivity (>208 PRU by VerifyNow P2Y12 test) was observed less frequently than expected," said Dietmar Trenk PhD. Dr. Trenk is Professor and Head of Clinical Pharmacology at Herz-Zentrum Bad Krozingen in Germany.

Dr. Trenk noted that the trial demonstrated that compared with standard-dose clopidogrel 75 mg, prasugrel 10 mg substantially decreased platelet reactivity in patients with high on-clopidogrel platelet reactivity after elective PCI.

"Given the low event rate in elective PCI patients without peri-procedural complications, it was not possible to assess the risk/benefit ratio with prasugrel treatment. Therefore, the study was terminated prematurely for futility," Dr. Trenk said.
-end-
The trial is sponsored by Eli Lilly and Company and Daiichi Sankyo Co., Ltd. Dr. Trenk reported consulting fees/honoraria and speaker honoraria from both companies, AstraZeneca and Sanofi-Aventis.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies, drugs and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.

For more information, visit www.crf.org.

Cardiovascular Research Foundation

Related Cardiac Death Articles from Brightsurf:

Sudden cardiac death often a woman's first sign of heart disease
New research from the Center for Cardiac Arrest Prevention at the Smidt Heart Institute at Cedars-Sinai shows that rates of sudden cardiac arrest are rising following decades of a downward trend.

New research could reduce the risk of sudden cardiac death
New research has shown that by changing the time course of voltage change early in action potential it is possible to both withhold a potentially lethal electrical disturbance and improve the strength of cardiac contraction in heart failure at the same time.

Rare genetic variants predispose to sudden cardiac death
By identifying rare DNA variants that substantially increase risk of sudden cardiac death, researchers have laid the foundation for efforts to identify individuals who could benefit from prevention strategies prior to experiencing symptoms.

Study: Cholesterol in eggs tied to cardiac disease, death
The risk of heart disease and death increases with the number of eggs an individual consumes, according to a UMass Lowell nutrition expert who has studied the issue.

New tool better at predicting death after cardiac admission than current indexes
A new tool designed for patients with heart disease is better at predicting death after hospital admission than current tools, according to a study published in CMAJ (Canadian Medical Association Journal).

PTSD linked to increased complications and death a year after cardiac arrest
Post-traumatic stress disorder (PTSD) symptoms may significantly increase cardiac arrest survivors' risk of major cardiovascular events and death up to a year after the initial medical crisis, according to preliminary research to be presented in Chicago at the American Heart Association's Resuscitation Science Symposium 2018 -- an international conference highlighting the best in cardiovascular resuscitation research.

Preventing sudden cardiac death with genome editing
Gene editing successfully prevented sudden cardiac death in a mouse model of inherited cardiac arrhythmia disorder.

Wearable defibrillator lowers sudden cardiac death, but only when you wear it
An international clinical trial that studied wearable cardioverter defibrillators (WCDs) found that the devices did not significantly reduce sudden cardiac death -- the primary goal of the device -- among patients assigned to the device in the first 90 days after a heart attack, but did lower mortality among those who wore it as prescribed, according to a study led by researchers at UC San Francisco.

Blood thinner significantly reduces the risk of death after non-cardiac surgery
The study enrolled 1,754 patients in 19 countries, 51 percent of whom were male, with an average age of 70 years.

New model estimates odds of events that trigger sudden cardiac death
A new computational model of heart tissue allows researchers to estimate the probability of rare heartbeat irregularities that can cause sudden cardiac death.

Read More: Cardiac Death News and Cardiac Death Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.